目标和范围:《人类疫苗与免疫疗法》是唯一一本专注于人类疫苗和免疫疗法的同行评审期刊。《华尔街日报》每年出版12期，主要以原创研究文章和评论的形式出版，并以评论和新闻更新为特色。还包括关于一个引起高度兴趣的重点主题的文章和评论的专题，以及完全致力于这一主题或著名国际会议文章的专题。该期刊拥有广泛而杰出的国际编辑委员会成员和副编辑委员会。该杂志从提交到接受再到出版的周转时间相对较快。人类疫苗与免疫疗法(HV&I)为展示和讨论疫苗学和免疫疗法的前沿研究和发展提供了一个平台。我们的杂志汇集了在以下领域工作的科学家、医生、公共卫生从业者和分析人员:研究和开发新的疫苗和免疫疗法实验疫苗和免疫治疗的新方法用于治疗非传染性疾病，如癌症的疫苗和免疫疗法临床前研究和临床试验许可产品及其在该领域的使用许可疫苗和免疫疗法对疾病的影响许可疫苗的安全性和认知发展中国家的预防和治疗流行病学和广泛HV&I提供多种格式，包括原始研究文章、简短报告、案例报告、评论和评论。
Aims & Scope: Human Vaccines & Immunotherapeutics is the only peer-reviewed journal focused on vaccines and immunotherapeutics for humans. The journal publishes 12 issues per year, mostly as original research articles and reviews, and also features commentaries and news updates. Also included are Special Features of articles and reviews on a focused theme of high interest as well as Special Issues devoted entirely to one such topic or to articles from prestigious international conferences.The journal is fully indexed with a broad and distinguished international panel of Editorial Board members and Associate Editors Editorial Board. The journal enjoys relatively rapid turnaround time from submission to acceptance to publication.Human Vaccines & Immunotherapeutics (HV&I) provides a platform for presenting and discussing cutting-edge research and developments in vaccinology and immunotherapy. Our journal brings together scientists, physicians, public health practitioners, and analysts working in the areas of: research and development of novel vaccines and immunotherapeutics experimental vaccines and novel approaches in vaccination and immunotherapy vaccines and immunotherapeutics for treating non-infectious diseases, e.g., cancer preclinical studies and clinical trials licensed products and their use in the field impact of licensed vaccines and Immunotherapeutics on disease safety and perceptions of licensed vaccines prevention and treatment in the developing world epidemiology and pharmaco-economicsHV&I offers a variety of formats including Original Research articles, Short Reports, Case Reports, Reviews, and Commentaries.
